The stock of Advanced Oncotherapy PLC (LON:AVO) hit a new 52-week low and has GBX 87.53 target or 10.00% below today’s GBX 97.25 share price. The 6 months bearish chart indicates high risk for the GBX 69.57M company. The 1-year low was reported on Nov, 8 by Barchart.com. If the GBX 87.53 price target is reached, the company will be worth GBX 6.96M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock decreased 2.75% or GBX 2.75 on November 8, hitting GBX 97.25. About 41,617 shares traded hands. Advanced Oncotherapy PLC (LON:AVO) has declined 42.86% since April 8, 2016 and is downtrending. It has underperformed by 44.81% the S&P500.
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The company has a market cap of 69.57 million GBP. The Firm is engaged in development and then building of the Linac Image Guided Hadron Technology proton beam cancer therapy device and management of healthcare related property. It currently has negative earnings. The Company’s divisions include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.